Killer Cell

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 72171 Experts worldwide ranked by ideXlab platform

Michael Boyiadzis - One of the best experts on this subject based on the ideXlab platform.

Frederic Bosco - One of the best experts on this subject based on the ideXlab platform.

  • multifunctional natural Killer Cell engagers targeting nkp46 trigger protective tumor immunity
    Cell, 2019
    Co-Authors: Laurent Gauthier, Ariane Morel, Nadia Anceriz, Benjamin Rossi, Audrey Blanchardalvarez, Gwendoline Grondin, Sylvia Trichard, Cedric Cesari, Melody Sapet, Frederic Bosco
    Abstract:

    Summary Over the last decade, various new therapies have been developed to promote anti-tumor immunity. Despite interesting clinical results in hematological malignancies, the development of bispecific Killer-Cell-engager antibody formats directed against tumor Cells and stimulating anti-tumor T Cell immunity has proved challenging, mostly due to toxicity problems. We report here the generation of trifunctional natural Killer (NK) Cell engagers (NKCEs), targeting two activating receptors, NKp46 and CD16, on NK Cells and a tumor antigen on cancer Cells. Trifunctional NKCEs were more potent in vitro than clinical therapeutic antibodies targeting the same tumor antigen. They had similar in vivo pharmacokinetics to full IgG antibodies and no off-target effects and efficiently controlled tumor growth in mouse models of solid and invasive tumors. Trifunctional NKCEs thus constitute a new generation of molecules for fighting cancer. Video Abstract Download : Download video (38MB)

  • multifunctional natural Killer Cell engagers targeting nkp46 trigger protective tumor immunity
    Cell, 2019
    Co-Authors: Laurent Gauthier, Ariane Morel, Nadia Anceriz, Benjamin Rossi, Audrey Blanchardalvarez, Gwendoline Grondin, Sylvia Trichard, Cedric Cesari, Melody Sapet, Frederic Bosco
    Abstract:

    Summary Over the last decade, various new therapies have been developed to promote anti-tumor immunity. Despite interesting clinical results in hematological malignancies, the development of bispecific Killer-Cell-engager antibody formats directed against tumor Cells and stimulating anti-tumor T Cell immunity has proved challenging, mostly due to toxicity problems. We report here the generation of trifunctional natural Killer (NK) Cell engagers (NKCEs), targeting two activating receptors, NKp46 and CD16, on NK Cells and a tumor antigen on cancer Cells. Trifunctional NKCEs were more potent in vitro than clinical therapeutic antibodies targeting the same tumor antigen. They had similar in vivo pharmacokinetics to full IgG antibodies and no off-target effects and efficiently controlled tumor growth in mouse models of solid and invasive tumors. Trifunctional NKCEs thus constitute a new generation of molecules for fighting cancer. Video Abstract

Miroslaw J Szczepanski - One of the best experts on this subject based on the ideXlab platform.

Laurent Gauthier - One of the best experts on this subject based on the ideXlab platform.

  • multifunctional natural Killer Cell engagers targeting nkp46 trigger protective tumor immunity
    Cell, 2019
    Co-Authors: Laurent Gauthier, Ariane Morel, Nadia Anceriz, Benjamin Rossi, Audrey Blanchardalvarez, Gwendoline Grondin, Sylvia Trichard, Cedric Cesari, Melody Sapet, Frederic Bosco
    Abstract:

    Summary Over the last decade, various new therapies have been developed to promote anti-tumor immunity. Despite interesting clinical results in hematological malignancies, the development of bispecific Killer-Cell-engager antibody formats directed against tumor Cells and stimulating anti-tumor T Cell immunity has proved challenging, mostly due to toxicity problems. We report here the generation of trifunctional natural Killer (NK) Cell engagers (NKCEs), targeting two activating receptors, NKp46 and CD16, on NK Cells and a tumor antigen on cancer Cells. Trifunctional NKCEs were more potent in vitro than clinical therapeutic antibodies targeting the same tumor antigen. They had similar in vivo pharmacokinetics to full IgG antibodies and no off-target effects and efficiently controlled tumor growth in mouse models of solid and invasive tumors. Trifunctional NKCEs thus constitute a new generation of molecules for fighting cancer. Video Abstract Download : Download video (38MB)

  • multifunctional natural Killer Cell engagers targeting nkp46 trigger protective tumor immunity
    Cell, 2019
    Co-Authors: Laurent Gauthier, Ariane Morel, Nadia Anceriz, Benjamin Rossi, Audrey Blanchardalvarez, Gwendoline Grondin, Sylvia Trichard, Cedric Cesari, Melody Sapet, Frederic Bosco
    Abstract:

    Summary Over the last decade, various new therapies have been developed to promote anti-tumor immunity. Despite interesting clinical results in hematological malignancies, the development of bispecific Killer-Cell-engager antibody formats directed against tumor Cells and stimulating anti-tumor T Cell immunity has proved challenging, mostly due to toxicity problems. We report here the generation of trifunctional natural Killer (NK) Cell engagers (NKCEs), targeting two activating receptors, NKp46 and CD16, on NK Cells and a tumor antigen on cancer Cells. Trifunctional NKCEs were more potent in vitro than clinical therapeutic antibodies targeting the same tumor antigen. They had similar in vivo pharmacokinetics to full IgG antibodies and no off-target effects and efficiently controlled tumor growth in mouse models of solid and invasive tumors. Trifunctional NKCEs thus constitute a new generation of molecules for fighting cancer. Video Abstract

Marta Szajnik - One of the best experts on this subject based on the ideXlab platform.

Killer Cell - 15 days free trial to Access Experts & Abstracts